Inhaled pan-phosphodiesterase inhibitors ameliorate ovalbumin-induced airway inflammation and remodeling in murine model of allergic asthma

Bush, 2019, Pathophysiological Mechanisms of Asthma, Front. Pediatr., 7, 10.3389/fped.2019.00068 Hough, 2020, Airway Remodeling in Asthma, Front. Med., 7, 191, 10.3389/fmed.2020.00191 Fehrenbach, 2017, Airway remodeling in asthma: what really matters, Cell Tissue Res., 367, 551, 10.1007/s00441-016-2566-8 Kuruvilla, 2019, Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease, Clin. Rev. Allergy Immunol., 56, 219, 10.1007/s12016-018-8712-1 Boulet, 2017, Airway remodeling in asthma: Mechanisms, clinical relevance, treatment, and prevention, Can. J. Respir. Crit. Care, Sleep Med., 1, 39 Boulet, 2018, Airway remodeling in asthma: update on mechanisms and therapeutic approaches, Curr. Opin. Pulm. Med., 24, 56, 10.1097/MCP.0000000000000441 Kistemaker, 2019, Airway Innervation and Plasticity in Asthma, Physiology (Bethesda)., 34, 283 Saglani, 2015, Novel concepts in airway inflammation and remodelling in asthma, Eur. Respir. J., 46, 1796, 10.1183/13993003.01196-2014 Papi, 2020, Treatment strategies for asthma: reshaping the concept of asthma management, Allergy, Asthma Clin. Immunol., 16, 75, 10.1186/s13223-020-00472-8 Witt, 2022, Overview of recent advancements in asthma management, Intern, Med. J., 52, 1478 GINA, 2022, Gina Main Report 2022 Pelaia, 2020, Molecular Targets for Biological Therapies of Severe Asthma, Front. Immunol., 11, 10.3389/fimmu.2020.603312 Edris, 2019, Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis, Respir. Res., 20, 179, 10.1186/s12931-019-1138-3 Varricchi, 2022, Biologics and airway remodeling in severe asthma, Allergy., 77, 3538, 10.1111/all.15473 Page, 2014, Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease, Int. Arch. Allergy Immunol., 165, 152, 10.1159/000368800 Matera, 2021, New Avenues for Phosphodiesterase Inhibitors in Asthma, J. Exp. Pharmacol., 13, 291, 10.2147/JEP.S242961 Zuo, 2019, Phosphodiesterases as therapeutic targets for respiratory diseases, Pharmacol. Ther., 197, 225, 10.1016/j.pharmthera.2019.02.002 Tilley, 2011, Methylxanthines in asthma, Handb. Exp. Pharmacol., 439, 10.1007/978-3-642-13443-2_17 Chłoń-Rzepa, 2018, Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain, Eur. J. Med. Chem., 158, 517, 10.1016/j.ejmech.2018.09.021 Chłoń-Rzepa, 2018, Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation, Eur. J. Med. Chem., 146, 381, 10.1016/j.ejmech.2018.01.068 Wójcik-Pszczoła, 2021, Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents, Bioorg. Chem., 117, 10.1016/j.bioorg.2021.105409 Wójcik-Pszczoła, 2020, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling, Int. J. Mol. Sci., 21, 10.3390/ijms21114008 Wójcik-Pszczoła, 2019, Novel phosphodiesterases inhibitors from the group of purine-2,6-dione derivatives as potent modulators of airway smooth muscle cell remodelling, Eur. J. Pharmacol., 865, 172779, 10.1016/j.ejphar.2019.172779 Wójcik-Pszczoła, 2022, Pan-Phosphodiesterase Inhibitors Attenuate TGF-β-Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation, Pharmaceuticals (Basel)., 15, 423, 10.3390/ph15040423 Wójcik-Pszczoła, 2022, In silico and in vitro ADME-Tox analysis and in vivo pharmacokinetic study of representative pan-PDE inhibitors from the group of 7,8-disubstituted derivatives of 1,3-dimethyl-7H-purine-2,6-dione, Toxicol. Appl. Pharmacol., 457, 116318, 10.1016/j.taap.2022.116318 Sakkas, 2017, Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives, Curr. Med. Chem., 24, 3054, 10.2174/0929867324666170530093902 Crocetti, 2022, An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022, Molecules., 27, 10.3390/molecules27154964 Phillips, 2020, Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases, Front. Pharmacol., 11, 259, 10.3389/fphar.2020.00259 Choi, 2021, Vinpocetine alleviates lung inflammation via macrophage inflammatory protein-1β inhibition in an ovalbumin-induced allergic asthma model, PLoS One., 16, e0251012, 10.1371/journal.pone.0251012 Clayton, 2004, The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma, Respir. Res., 5, 4, 10.1186/1465-9921-5-4 Kim, 2016, Effect of roflumilast on airway remodelling in a murine model of chronic asthma, Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol., 46, 754, 10.1111/cea.12670 Kim, 2022, The effects of BRL-50481 on ovalbumin-induced asthmatic lung inflammation exacerbated by co-exposure to Asian sand dust in the murine model, Arch. Pharm. Res., 45, 51, 10.1007/s12272-021-01367-x Urbanova, 2016, Bronchodilator and Anti-Inflammatory Action of Theophylline in a Model of Ovalbumin-Induced Allergic Inflammation, Adv. Exp. Med. Biol., 935, 53, 10.1007/5584_2016_31 Lee, 2020, Inhibition of phosphodiesterase suppresses allergic lung inflammation by regulating MCP-1 in an OVA-induced asthma murine model with co-exposure to lipopolysaccharide, J. Int. Med. Res., 48, 10.1177/0300060520903663 Nakae, 2007, Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice, J. Allergy Clin. Immunol., 120, 48, 10.1016/j.jaci.2007.02.046 Mäkelä, 2000, IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization, Proc. Natl. Acad. Sci. USA, 97, 6007, 10.1073/pnas.100118997 Lee, 2004, Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung, Nat. Med., 10, 1095, 10.1038/nm1105 Chetta, 2012, Role of Inhaled Steroids in Vascular Airway Remodelling in Asthma and COPD, Int. J. Endocrinol., 2012, 10.1155/2012/397693 Baraket, 2012, Is low dose inhaled corticosteroid therapy as effective for inflammation and remodeling in asthma? A randomized, parallel group study, Respir. Res., 13, 11, 10.1186/1465-9921-13-11 Bullone, 2017, Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma, Sci. Rep., 7, 8843, 10.1038/s41598-017-09414-8 Berair, 2014, Asthma therapy and its effect on airway remodelling, Drugs., 74, 1345, 10.1007/s40265-014-0250-4 Elliot, 2018, Inflammation-dependent and independent airway remodelling in asthma, Respirology., 23, 1138, 10.1111/resp.13360 Caminati, 2021, Uncontrolled Asthma: Unmet Needs in the Management of Patients, J. Asthma Allergy., 14, 457, 10.2147/JAA.S260604 Adatia, 2022, Challenges in severe asthma: Do we need new drugs or new biomarkers?, Front. Med., 9, 10.3389/fmed.2022.921967 Bellanti, 2015, Addressing the challenges of severe asthma, Allergy Asthma Proc., 36, 237, 10.2500/aap.2015.36.3874 Barnes, 2013, Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease, J. Allergy Clin. Immunol., 131, 636, 10.1016/j.jaci.2012.12.1564 Wadhwa, 2019, Cellular mechanisms underlying steroid-resistant asthma, Eur. Respir. Rev., 28, 190096, 10.1183/16000617.0096-2019 Price, 2018, Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study, J. Asthma Allergy., 11, 193, 10.2147/JAA.S176026 Volmer, 2018, Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature, Eur. Respir. J., 52, 1800703, 10.1183/13993003.00703-2018 Daugherty, 2018, The impact of long-term systemic glucocorticoid use in severe asthma: A UK retrospective cohort analysis, J. Asthma., 55, 651, 10.1080/02770903.2017.1353612 Cazzola, 2018, Efficacy and safety profile of xanthines in COPD: a network meta-analysis, Eur. Respir. Rev. an Off. J. Eur. Respir. Soc., 27, 180010, 10.1183/16000617.0010-2018 Barnes, 2010, Theophylline, Pharmaceuticals (Basel)., 3, 725, 10.3390/ph3030725 Eid, 2016, Anti-inflammatory dosing of theophylline in the treatment of status asthmaticus in children, J. Asthma Allergy., 9, 183, 10.2147/JAA.S113747 Cazzola, 2016, The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease, Expert Opin. Drug Discov., 11, 733, 10.1080/17460441.2016.1184642 Singh, 2019, Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD, Respir. Res., 20, 180, 10.1186/s12931-019-1142-7 Singh, 2021, Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease, Drugs., 81, 1821, 10.1007/s40265-021-01616-9 Martin, 2021, Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review, Int. J. Chron. Obstruct. Pulmon. Dis., 16, 2363, 10.2147/COPD.S226688 Facchinetti, 2021, Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease, Front. Pharmacol., 12, 10.3389/fphar.2021.740803 Sun, 2020, Theophylline and dexamethasone in combination reduce inflammation and prevent the decrease in HDAC2 expression seen in monocytes exposed to cigarette smoke extract, Exp Ther Med., 19, 3425 Ranjani, 2017, A prospective randomized controlled study: Theophylline on oxidative stress and steroid sensitivity in chronic obstructive pulmonary disease patients, Int. J. Pharm. Investig., 7, 119, 10.4103/jphi.JPHI_58_17 Cosio, 2009, Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD, Thorax., 64, 424, 10.1136/thx.2008.103432